CD2 Antigens

Glycoprotein members of the immunoglobulin superfamily which participate in T-cell adhesion and activation. They are expressed on most peripheral T-lymphocytes, natural killer cells, and thymocytes, and function as co-receptors or accessory molecules in the T-cell receptor complex.

Also Known As:

Networked: 31 relevant articles (0 outcomes, 5 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Valent, Peter: 3 articles (01/2006 - 02/2002)
2.	Horny, Hans-Peter: 2 articles (07/2003 - 02/2002)
3.	Hou, W H: 1 article (04/2022)
4.	Wang, Xu: 1 article (04/2022)
5.	Xie, J L: 1 article (04/2022)
6.	Zhang, X: 1 article (04/2022)
7.	Zheng, Y L: 1 article (04/2022)
8.	Zhou, X G: 1 article (04/2022)
9.	Biernat, Wojciech: 1 article (01/2014)
10.	Jassem, Ewa: 1 article (01/2014)

Related Diseases

1.	Neoplasms (Cancer) 12/01/1996 - "We examined the prognostic impact of CD2 antigen expression for 651 patients with T-lineage acute lymphoblastic leukemia (ALL), who were enrolled in front-line Childrens Cancer Group treatment studies between 1983 and 1994. " 12/01/2023 - "To broaden the use of CAR-T cells in pan T-cell malignancies, we developed an allogeneic "universal" CD2-targeting CAR-T cell (UCART2), in which the CD2 antigen is deleted to prevent fratricide, and the T-cell receptor is removed to prevent GvHD. " 04/08/2022 - "Immunohistochemical staining showed that tumor cells expressed T cell antigens (CD2, CD3, CD5, and CD7), and 72.0% (77/107) of them had decreased or lost expression of one or more antigens. " 04/01/1990 - "In two cases the tumor cells acquired the CD7 antigen or lost the CD2 antigen with progression of the disease. " 12/01/1996 - "CD2 antigen expression on leukemic cells as a predictor of event-free survival after chemotherapy for T-lineage acute lymphoblastic leukemia: a Children's Cancer Group study."
2.	Systemic Mastocytosis 12/01/1995 - "In this study the expression of 'classically' considered lymphoid-associated antigens (CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD19, CD20, and CD22) was explored both in peripheral blood (PB) and bone marrow (BM) mast cells (MC) in a case of systemic mast cell disease (SMCD) by means of using multiple stainings and a direct immunofluorescence technique. " 01/01/2006 - "Several of these antigens (CD2, CD25, CD35, CD88, CD203c) appear to be upregulated on MCs in patients with systemic mastocytosis and therefore are used as diagnostic markers. " 07/01/2003 - "As assessed by immunohistochemistry, mast cells were immunoreactive for tryptase and CD68R, In contrast, the CD2 antigen that is expressed in mast cells in patients with indolent systemic mastocytosis was not detectable. "
3.	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 12/01/1996 - "We examined the prognostic impact of CD2 antigen expression for 651 patients with T-lineage acute lymphoblastic leukemia (ALL), who were enrolled in front-line Childrens Cancer Group treatment studies between 1983 and 1994. " 12/01/1996 - "CD2 antigen expression on leukemic cells as a predictor of event-free survival after chemotherapy for T-lineage acute lymphoblastic leukemia: a Children's Cancer Group study." 05/01/1988 - "We constructed a series of MAb heterodimers consisting of the J5 (anti-common acute lymphoblastic leukemia antigen [CALLA]) antibody and antibodies to a variety of structures present on the surface of activated human T cells, including CD3 antigen (T cell receptor-associated glycoproteins), CD2 antigen (T11/E-rosette receptor), CD25 antigen (IL-2 receptor), and the transferrin receptor. "
4.	Infections 12/15/1998 - "In the present study we report that the expression of both CD4 and CD2 antigen is down-regulated during the acute phase of infection. " 09/01/1998 - "Approximately 20% of PB and MLN lymphocytes had lost CD2 antigen in the males with combined splenectomy and nephrectomy, one of which died of severe infection. "
5.	Histiocytic Necrotizing Lymphadenitis (Kikuchi Disease) 12/01/2011 - "[Loss of pan-T cell antigens CD2, CD3, CD5 and CD7 in Kikuchi's disease]." 12/01/2011 - "To study the possible loss of pan-T cell antigens CD2, CD3, CD5 and CD7 in Kikuchi's disease and to evaluate the role of T cell antigen loss in distinguishing benign from malignant T-cell lymphoid lesions. "

Related Drugs and Biologics

1.	Antigens
2.	Monoclonal Antibodies
3.	gamma-delta T-Cell Antigen Receptors (T-Cell Receptor delta-Chain)
4.	Heat-Shock Proteins (Heat-Shock Protein)
5.	Tryptases (Tryptase)
6.	CD7 Antigens
7.	CD13 Antigens (Alanine Aminopeptidase)
8.	Transferrin Receptors (Transferrin Receptor)
9.	T-Cell Antigen Receptors (T-Cell Receptor)
10.	Granzymes (Granzyme)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Splenectomy
4.	Nephrectomy